Aerie Pharmaceuticals Announced Exclusive License Agreement With Santen for Rhopressa and Rocklatan in Europe and Several Other Regions; Aeries to Receive Upfront Payment of $88M, Various Milestones of up to $77M, Plus Additional Consideration in Excess of 25% of Products’ Net Sales